Last verified: April 2026

Inhalation — The Fastest Onset

Inhalation remains the most pharmacokinetically efficient route for cannabinoid delivery. THC reaches the brain within seconds to minutes, producing peak plasma concentrations of approximately 152 ng/mL within 3–10 minutes of smoking. Bioavailability ranges from 10% to 35%, depending on inhalation technique, device efficiency, and individual pulmonary function (Huestis 2007, Chemistry & Biodiversity).

The wide bioavailability range reflects real-world variability: experienced users who take deep inhalations and hold briefly achieve the upper end, while casual users with shallow draws may absorb less than 15%. The speed of onset allows users to titrate dose in near real-time — a significant clinical advantage over oral administration.

Smoking vs. Vaporization

Combustion occurs at approximately 900°C (the tip of a lit joint), which destroys a substantial proportion of cannabinoids. Only about 10% of available cannabinoids survive combustion intact. The remainder pyrolyze into a mixture of over 100 identified compounds, including polycyclic aromatic hydrocarbons, carbon monoxide, and tar — many of the same toxicants found in tobacco smoke.

Vaporization heats cannabis to 180–210°C, below the combustion threshold but above the boiling points of major cannabinoids. This captures up to 95% of available cannabinoids while dramatically reducing toxicant exposure. The boiling points of individual cannabinoids determine selective extraction: THC vaporizes at 157°C, CBD at 160–180°C, and CBN at 185°C. Temperature-controlled devices exploit these thresholds to preferentially deliver specific cannabinoid profiles.

The EVALI Crisis

The vaping-associated lung injury outbreak of 2019–2020 hospitalized 2,807 people and killed 68 across the United States. Blount et al. (2020, New England Journal of Medicine) identified vitamin E acetate as the primary causative agent, detecting it in bronchoalveolar lavage fluid of 48 out of 51 EVALI patients. Critically, approximately 80% of cases involved products purchased from unregulated sources, highlighting the safety differential between legal and illicit markets.

Vitamin E acetate was identified in bronchoalveolar lavage fluid from 48 of 51 case patients (94%) but not in fluid from the healthy comparator group.

Blount et al., NEJM 2020

Vitamin E acetate was used as a cutting agent in illicit THC vape cartridges to increase volume and visual viscosity. When inhaled and heated, it coats alveolar surfaces, interfering with surfactant function and triggering lipoid pneumonia. The outbreak effectively ended after public health campaigns warned against unregulated cartridges, though sporadic cases continue.

Oral Administration — The 11-OH-THC Problem

Oral cannabis undergoes extensive first-pass hepatic metabolism via CYP2C9, converting delta-9-THC to 11-hydroxy-THC (11-OH-THC) — a metabolite that is 1.5 to 7 times more potent at CB1 receptors and crosses the blood-brain barrier more readily. This metabolic transformation fundamentally changes the pharmacological character of the dose.

Oral bioavailability is 4–20%, substantially lower than inhalation, with onset delayed to 30–90 minutes and duration extended to 4–12 hours. Co-administration with lipids increases absorption by approximately 2.8-fold, which explains why many commercial edibles are formulated in fat-based matrices. The unpredictable onset and extended duration create clinical challenges: patients who re-dose after 45 minutes — believing the first dose "didn't work" — risk delayed double-dosing, the most common cause of cannabis-related emergency department visits from edibles.

Sublingual, Topical, and Transdermal

Sublingual administration partially bypasses first-pass metabolism by delivering cannabinoids across the oral mucosa directly into venous circulation. Sativex (nabiximols), the oromucosal THC:CBD spray approved in over 29 countries for MS spasticity, uses this route to achieve more predictable pharmacokinetics than oral dosing while avoiding the pulmonary risks of inhalation. Onset is typically 15–30 minutes — intermediate between inhalation and oral.

Topical formulations (creams, balms, salves) deliver cannabinoids only to local tissue. Cannabinoids are highly lipophilic and penetrate poorly beyond the dermis, meaning topicals produce no systemic effects and no psychoactivity. They interact with CB1 and CB2 receptors in cutaneous tissue, keratinocytes, and peripheral nerve endings. Clinical evidence is limited primarily to preclinical models of localized inflammation and pain.

Transdermal patches are pharmacologically distinct from topicals. Engineered with permeation enhancers, they deliver cannabinoids through the skin and into systemic circulation over 12–24 hours, producing measurable plasma levels. This route provides sustained, steady-state delivery without first-pass metabolism — potentially advantageous for chronic conditions requiring consistent plasma concentrations.

Rectal Administration — The Overlooked Route

Rectal delivery achieves bioavailability of 70–80% (ElSohly et al. 2018), substantially higher than any other non-inhalation route. Because rectal venous drainage partially bypasses the portal system, this route produces less 11-OH-THC than oral administration, altering the metabolite profile and potentially reducing psychoactivity relative to an equivalent oral dose.

Despite pharmacokinetic advantages, cultural stigma limits adoption. The primary clinical use has been in pediatric seizure management for patients unable to take oral medications — particularly children with intractable epilepsy who are vomiting or unconscious. Rectal formulations allow precise dosing and reliable absorption in these emergency situations.

Nano-Emulsions — Emerging Technology

Nano-emulsion technology reduces cannabinoid particle size to below 200 nanometers, creating water-compatible formulations that dramatically improve absorption kinetics. These formulations achieve approximately 3–4 times greater bioavailability compared to conventional oil-based edibles, with onset reduced to 10–30 minutes — approaching sublingual speeds via the oral route.

The technology works by creating micelle structures that protect lipophilic cannabinoids in aqueous environments and present them to intestinal epithelium in a form that facilitates rapid absorption. Several commercial edible and beverage manufacturers have adopted nano-emulsion processes, marketing products with "fast-acting" onset claims. The pharmacokinetic improvements are well-documented in vitro and in limited clinical studies, though long-term safety data on nano-particle formulations remains sparse.

Clinical Implications — Matching Route to Patient

Route selection should be driven by clinical need, not consumer preference. Acute conditions (breakthrough pain, panic attacks, acute nausea) favor inhalation for rapid onset and real-time titration. Chronic conditions (spasticity, neuropathic pain, insomnia) benefit from oral or transdermal routes that provide extended duration. Patients on concurrent medications metabolized by CYP2C9 may need to avoid oral routes that maximize 11-OH-THC formation. And patients who cannot tolerate any psychoactivity should consider topical applications that provide local effects without systemic absorption.

The critical takeaway: the same 10 mg of THC produces fundamentally different pharmacological experiences depending on how it enters the body. Onset ranges from seconds to 90 minutes. Duration ranges from 2 to 12 hours. The active metabolite profile changes. The subjective experience changes. Route of administration is not a detail — it is a primary determinant of clinical outcome.